One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Human Growth Hormone (HGH) Market

[ 英語タイトル ] Human Growth Hormone (HGH) Market - Growth, Trends, and Forecasts (2020 - 2025)

Product Code : MDHC0082584
Survey : Mordor Intelligence
Publish On : November, 2020
Category : Healthcare and Pharmaceuticals
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - AnkeBio Co. Ltd
- EMD Serono Inc.
- F. Hoffmann-La Roche Ltd
- Ferring BV
- Ipsen
- Eli Lilly and Company
- Novo Nordisk A/S
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd

[Report Description]

The human growth hormone or somatotropin helps to stimulate growth, regeneration, and reproduction. The increase in applications of growth hormone and the awareness about the effects of growth hormone in the treatment of short stature are major factors propelling the growth of this market. Most of the companies are investing in R&D for developing a growth hormone that has fewer side effects and will be long-acting hormonal therapy. Technical developments in the recombinant human growth hormone are also expected to boost the growth of the human growth hormone market over the forecast period.

Key Market Trends

By Application, Turner Syndrome Segment is Expected to Register Steady Growth.

Turner syndrome is a rare chromosomal disorder that affects females, characterized by the partial or complete loss of one of the X chromosomes. The symptoms of Turner syndrome include a wide neck and a low or indistinct hairline, tendency to develop high blood pressure, minor eye problems, drooping of the eyelids, and under-active thyroid gland. The age of diagnosis has been decreasing with better awareness of Turner syndrome in the medical community, which, in turn, is driving the studied market. Since it is associated with many complications related to heart, hearing loss, autoimmune disorders, mental health issues, infertility, and pregnancy complications, the demand for treatment involving growth hormones is increasing.

North America to Dominate the Market

The United States accounted for the largest market share. The dominance of this country can be attributed to factors, such as high healthcare expenditure, and the availability of reimbursements. In the United States, approximately one in 4,000 to 10,000 children suffer from growth hormone deficiency and approximately 50,000 adults have growth hormone deficiency, with about 6,000 new adult patients diagnosed every year. Recombinant growth hormone has been widely available for prescription use in the United States. It is used for growth hormone deficiency (GHD), Turner's syndrome, chronic renal insufficiency, small for gestational age or intrauterine growth retardation, Prader-Willi syndrome, continued height deficit at puberty, and cachexia, or AIDS wasting.

The Asia-Pacific region is anticipated to witness the fastest growth during the forecast period as the demand for growth hormone has been rising in the emerging countries for the past few years.

Competitive Landscape

The human growth hormone market is consolidated and highly competitive with a few market players controlling a significant share of the market. Furthermore, there are several active partnerships for the development of more efficacious and long-acting subtypes of human growth hormones.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Development of Recombinant Human Growth Hormone Drugs
4.2.2 Rise in Pituitary Dysfunction Cases
4.2.3 Rising Off-label Use of Human Growth Hormone
4.3 Market Restraints
4.3.1 Adverse Effects Associated with Human Growth Hormone
4.3.2 Stringent Regulatory Processes
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Application
5.1.1 Growth Hormone Deficiency
5.1.2 Turner Syndrome
5.1.3 Idiopathic Short Stature
5.1.4 Prader-Willi Syndrome
5.1.5 Other Applications
5.2 By Distribution Channel
5.2.1 Hospital and Retail Pharmacy
5.2.2 Online Pharmacy
5.2.3 Others
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East & Africa GCC South Africa Rest of Middle-East & Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 AnkeBio Co. Ltd
6.1.2 EMD Serono Inc.
6.1.3 F. Hoffmann-La Roche Ltd
6.1.4 Ferring BV
6.1.5 Ipsen
6.1.6 Eli Lilly and Company
6.1.7 Novo Nordisk A/S
6.1.8 Pfizer Inc.
6.1.9 Teva Pharmaceutical Industries Ltd




Recommended reports